MICROALBUMINURIA IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS AND ITS CORRELATION WITH LEFT VENTRICULAR HYPERTROPHY”
DOI:
https://doi.org/10.59058/jaimc.v21i2.52Keywords:
Correlation, Hypertension Microalbumnuria, LVH, Ventricular HypertrophyAbstract
Background: One of the most important factors in the development of cardiovascular diseases worldwide is Hypertension. A reliable indicator and a diagnostic modality in early stage of renal diseases and predictor of atrial hypertension (AH) progression is microalbminurea (MAU) which is also an independent risk factor of cardiovascular mortality and death.
Objective: To determine the prevalence of microalbuminuria and left vertricular hypertrophy and assess correlation between micro albuminuria and LVH among newly diagnosed hypertensive patients.
Methods: A cross sectional study conducted in Medical Unit IV, Jinnah Hospial Lahore from January to June, 2022. About 146 adults newly diagnosed hypertensive patients were included for study. Blood pressure was measured using sphygmomanometer with standard cuff in sitting position, with two measurements were made at least 5 min apart. Microalbuminuria was defined as albumin excretion 30 to 300 mg/dl in a spot urine sample report. Left ventricular hypertrophy (LVH) is defined as presence of concentric hypertrophy or diastolic dysfunction determined on Trans Thoracic ECHO by a cardiologist. Data was entered in SPSS Ver: 25.0 for data analysis and graphical presentation. For quantitative variables like age, ACR; mean and standard deviation was calculated. Prevalence and correlation of MAU and LVH in newly diagnosed hypertensive patients was using Spearmen’s Rank Correlation Analysis. Chi-square test was performed to compare MAU and LVH. P-value of < 0.05 was considered statistically significant.
Results: 146 subjects those fulfilling the inclusion criteria were admitted. Mean age was 48.281 + 24.865. 72.6% were male in our study. 30.8% of patients had LVH and microbuminurea was present in 47.5% of subject. About 28.6% of patient with LVH had MAU. (p=.030). There was a positive correlation between LVH and MAU. (r=0.135, P =.002).
Conclusions: Our study concludes a high prevalence of micro albuminuria and LVH in newly diagnosed hypertensive. There is positive correlation between micro albuminuria and LVH and can be predictor of cardiovascular morbidity and mortality.
References
Saleem F, Hassali AA, Shafie AA. Hypertension in Pakistan: time to take some serious action. British Journal of General Practice 2010; 60: 449-450.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens 2020; 38: 982-1004.
Hamrah SM, Hamrah HM, Ishii, H, Suzuki S, Hamrah EA, Dahi EA, et al. Left ventricular hypertrophy and proteinuria in patients with essential hypertension in Andkhoy, Afghanistan. Nagoya J Med Sci 2018; 80: 249-255.
Zelveian PA, Dgerian LG. Microalbuminuria as an early indicator of renal lesion in arterial hypertension. Klin Med (Mosk) 2014; 92: 11-7.
Sharma SK, Aggarwal A, Dabadghao VS, Khese VB, Malik SK.Agarwal S. A Clinical Study of Prevalence of Microalbuminuria in Patients of Primary Hypertension and its Correlation with Left Ventricular Mass Index. J Assoc Physicians India 2019; 67: 24-26.
Nabbaale J, Kibirige D, Ssekasanvu E, Sebatta ES, Kayima J, Lwabi Pet al. Microalbuminuria and left ventricular hypertrophy among newly diagnosed black African hypertensive patients: a cross sectional study from a tertiary hospital in Uganda. BMC Research Notes 2015; 8: 198.
Monfared A, Salari A, Mirbolok F, Momeni M, Shafighnia S, Shakiba M, et al. Left ventricular hypertrophy and microalbuminuria in patients with essential hypertension. Iran J Kidney Dis 2013; 7: 192-7.
Maggon R, Malik R, Jain N, Isser H. Study of the Prevalence of Microalbuminuria in Patients of Essential Hypertension and its Correlation with Left Ventricular Hypertrophy and Carotid Artery Intima-media Thickness. Journal of Clinical and Preventive Cardiology 2018; 7: 11-16.
Rameez B, Raja AS, Anandan H. Microalbuminuria and its Correlation with Left Ventricular Hypertrophy and Retinopathy in Non-diabetic Hypertensive Patients. International Journal of Scientific Study 2017; 5: 5 -9.
Al-Sharifi A, Mingher HM. Microalbuminuria and left ventricular hypertrophy in with essential hypertension. Journal of the Pakistan Medical Association 2019; 69: 4 -9.
Santulli G. Epidemiology of Cardiovascular Disease in the 21st Century: updated numbers and updated fact. JCvD. 2013;1(1):1–2.
WHO. Cardiovascular diseases. Available at: http://www.who.int/mediacentre/factsheets/fs317/en. Accessed 26th January, 2022.
Abdelhafiz A, Ahmed S, El-Nahas M. Microalbuminuria: Marker or Maker of Cardiovascular Disease. Nephron Exp Nephrol. 2011;119(suppl 1):e6–e10. doi: 10.1159/000328015.
Stehouwer C, Smulders Y. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006; 17:2106–11. doi: 10.1681/ASN.2005121288.
Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of office blood pressure values. J Hypertens. 2009; 27:2458–64. doi: 10.1097/HJH.0b013e328330b845.
Rayner B, Becker P. The prevalence of MA and ECG LVH in hypertensive patients in private practices in South Africa. Cardiovasc J South Afr. 2006; 17:245–9.
Palmieri V, Celentano A, Roman J, de-Simone G, Lewis M, Best L, et al. Fibrinogen and preclinical echocardiographic target organ damage: the Strong Heart Study. Hypertension. 2001;38:1068–74.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Khalid Mehmood Khan, Muzammal Aslam kataria, Mohammad Saddam Rahman, Rehana Kanwal, Hassan Farooq, Rana Muhammad Arif
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published in this journal come under creative commons licence Attribution 4.0 International (CC BY 4.0) which allows to copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially under following terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The editorial board of the Journal strives hard for the authenticity and accuracy of the material published in the Journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board. Many software like (Google Maps, Google Earth, Biorender (free version)) restricts the free distribution of materials prepared using these softwares. Therefore, authors are strongly advised to check the license/copyright information of the software used to prepare maps/images. In case of publication of copyright material, the correction will be published in one of the subsequent issues of the Journal, and the authors will bear the printing cost.
